113 related articles for article (PubMed ID: 22044821)
1. Rituximab induced myocardial infarction: A fatal drug reaction.
Arunprasath P; Gobu P; Dubashi B; Satheesh S; Balachander J
J Cancer Res Ther; 2011; 7(3):346-8. PubMed ID: 22044821
[No Abstract] [Full Text] [Related]
2. Hepatitis B reactivation induced by Rituximab maintenance therapy for lymphoma.
Cho CH; Hwang WL; Cheng SB; Lee TY; Teng CL
Ann Hematol; 2011 Jan; 90(1):111-2. PubMed ID: 20407894
[No Abstract] [Full Text] [Related]
3. Focal rituximab-induced edematous reaction at primary cutaneous follicle center lymphoma lesions: case report and literature review.
Brunet-Possenti F; Franck N; Tamburini J; Jacobelli S; Avril MF; Dupin N
Dermatology; 2011; 223(3):200-2. PubMed ID: 21986026
[TBL] [Abstract][Full Text] [Related]
4. Fatal reactivation of occult hepatitis B virus infection after rituximab and chemotherapy in lymphoma: necessity of antiviral prophylaxis.
Zhang B; Wang J; Xu W; Wang L; Ni W
Onkologie; 2010; 33(10):537-9. PubMed ID: 20926902
[TBL] [Abstract][Full Text] [Related]
5. Rapid-onset, prolonged bone marrow failure following rituximab therapy of follicular lymphoma.
Debatin L; Schmitt-Graeff A; Veelken H
Onkologie; 2011; 34(6):322-4. PubMed ID: 21625186
[No Abstract] [Full Text] [Related]
6. Rituximab and lung disease.
O'Connor MB; Phelan MJ
Ir Med J; 2012 Oct; 105(9):314. PubMed ID: 23240291
[No Abstract] [Full Text] [Related]
7. Rituximab-induced acute severe thrombocytopenia: a case series in patients with mantle cell lymphoma.
Sadashiv SK; Rao R; Fazal S; Lister J
Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):602-5. PubMed ID: 23870855
[No Abstract] [Full Text] [Related]
8. Severe anemia during rituximab maintenance therapy for follicular lymphoma.
Liapis K; Harhalakis N; Stefanou G; Apostolidis J
J Clin Oncol; 2012 Mar; 30(8):e95-6. PubMed ID: 22231048
[No Abstract] [Full Text] [Related]
9. Rituximab-induced interstitial lung disease: case report and literature review.
Zayen A; Rais H; Rifi H; Ouarda M; Afrit M; Cherif A; Mezline A
Pharmacology; 2011; 87(5-6):318-20. PubMed ID: 21613805
[TBL] [Abstract][Full Text] [Related]
10. Malignancies after rituximab treatment: just coincidence or more?
Aksoy S; Arslan C; Harputluoglu H; Dizdar O; Altundag K
J BUON; 2011; 16(1):112-5. PubMed ID: 21674860
[TBL] [Abstract][Full Text] [Related]
11. [Subcutaneous Rituximab is effective and safe].
Häckel A
Med Monatsschr Pharm; 2014 Jan; 37(1):39-40. PubMed ID: 24490439
[No Abstract] [Full Text] [Related]
12. Rituximab-induced immunodysregulatory ileocolitis in a patient with follicular lymphoma.
Blombery P; Prince HM; Levinson M; Pianko S; Maxwell E; Bhathal P
J Clin Oncol; 2011 Feb; 29(5):e110-2. PubMed ID: 21098319
[No Abstract] [Full Text] [Related]
13. Is rituximab-induced late-onset neutropenia a good prognostic indicator in lymphoproliferatve disorders?
Hincks I; Woodcock BE; Thachil J
Br J Haematol; 2011 May; 153(3):411-3. PubMed ID: 21275972
[No Abstract] [Full Text] [Related]
14. Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma.
Huang YC; Liu CJ; Liu CY; Pai JT; Hong YC; Teng HW; Hsiao LT; Chao TC; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Yu YB; Tzeng CH
Ann Hematol; 2011 Oct; 90(10):1145-51. PubMed ID: 21647583
[TBL] [Abstract][Full Text] [Related]
15. Rituximab-related cryptogenic organizing pneumonia and late onset neutropenia in a patient with non-Hodgkin lymphoma: report of two rare complications and review of the literature.
Urun Y; Dincol D; Kumbasar OO
J BUON; 2012; 17(3):602-3. PubMed ID: 23033310
[No Abstract] [Full Text] [Related]
16. Safety and efficacy of rituximab in steroid-refractory chronic GVHD.
Clavert A; Chevallier P; Guillaume T; Delaunay J; Le Gouill S; Mahe B; Dubruille V; Gastinne T; Blin N; Moreau P; Mohty M
Bone Marrow Transplant; 2013 May; 48(5):734-6. PubMed ID: 23085828
[No Abstract] [Full Text] [Related]
17. Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study.
Tobinai K; Igarashi T; Itoh K; Kurosawa M; Nagai H; Hiraoka A; Kinoshita T; Uike N; Ogura M; Nawano S; Mori S; Ohashi Y;
Cancer Sci; 2011 Sep; 102(9):1698-705. PubMed ID: 21645173
[TBL] [Abstract][Full Text] [Related]
18. Rituximab-induced subacute interstitial pneumonitis: a case report and review of literature.
Subramanian M; Manjunath R; Kilara N; Mohan Rao KN
J Cancer Res Ther; 2010; 6(3):344-6. PubMed ID: 21119272
[TBL] [Abstract][Full Text] [Related]
19. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
20. Paradoxical immune reconstitution inflammatory syndrome associated with rituximab-containing regimen in a patient with lymphoma.
Canaani J; Amit S; Ben-Ezra J; Cohen Pour M; Sarid N; Lerman H; Perry C; Polliack A; Naparstek E; Herishanu Y
J Clin Oncol; 2013 Apr; 31(11):e178-80. PubMed ID: 23439758
[No Abstract] [Full Text] [Related]
[Next] [New Search]
